金斯瑞生物科技早盘涨超4% 礼新大额许可收入落地 传奇生物扭亏在即

Core Viewpoint - Kingsoft Biotech (01548) reported significant growth in its interim results, with a notable increase in revenue and a substantial reduction in losses, indicating a positive trajectory for the company [1] Financial Performance - The revenue from continuing operations reached $519 million, representing a year-on-year increase of 81.92% [1] - The loss attributable to the parent company narrowed to $25.46 million, a reduction of 85.46% compared to the previous year [1] - Adjusted net profit stood at $178 million, showing a remarkable year-on-year growth of 509.6% [1] CDMO Segment - The CDMO (Contract Development and Manufacturing Organization) revenue for the first half of the year was $250 million, reflecting a year-on-year increase of 511.1% [1] - A one-time prepayment related to the partnership with Lixin has been confirmed and received, amounting to $214 million, with a double-digit growth rate when excluding this amount [1] Impact of Joint Ventures - The joint venture with Legend Biotech resulted in a loss impact of $194 million for the first half of the year, affecting Kingsoft Biotech's net profit [1] - Legend Biotech is expected to achieve adjusted net profit in the second quarter of 2025 and aims for overall profitability by 2026 [1] - The core product CARVYKTI from Legend Biotech achieved net sales of $439 million in the second quarter of 2025, marking a year-on-year growth of 136%, which is anticipated to support Kingsoft Biotech's net profit improvement in 2026 [1]